Tumour suppressor gene signature predicts early progression in metastatic hormone-sensitive metastatic prostate cancer (mHSPC) patients

被引：0

作者：

Garcia De Herreros, M. ^{[1
]}

Jimenez Blasco, N. ^{[2
]}

Reig Torras, O. ^{[1
]}

Ferrer Mileo, L. ^{[1
]}

Aversa, C. ^{[1
]}

Garcia-Esteve, S. ^{[2
]}

Rodriguez-Carunchio, L. ^{[3
]}

Trias Puigsureda, I. ^{[3
]}

Padrosa, J. ^{[1
]}

Fernandez Manas, L. ^{[1
]}

Marin, M. ^{[2
]}

Font Pous, A. ^{[4
]}

Rodriguez-Vida, A. ^{[5
]}

Climent Duran, M. A. ^{[6
]}

Cros Costa, S. ^{[7
]}

Chirivella Gonzalez, I. ^{[8
]}

Figols Gorina, M. ^{[9
]}

Mellado Gonzalez, B. ^{[1
]}

机构：

[1] Hosp Clin Barcelona, Dept Med Oncol, Barcelona, Spain

[2] IDIBAPS Fundacio Recerca Clin Barcelona, Translat Genom & Targeted Therapeut Solid Tumors, Inst Invest Biomed August Pi & Sunyer, Barcelona, Spain

[3] Hosp Clin Barcelona, Dept Pathol, Barcelona, Spain

[4] Hosp Badalona Germans Trias & Pujol, Dept Oncol, ICO Inst Catala Oncol Badalona, Barcelona, Spain

[5] Hosp del Mar Parc Salut Mar, Dept Med Oncol, Barcelona, Spain

[6] IVO Fdn Inst Valenciano Oncol, Med Oncol, Valencia, Spain

[7] Hosp Gen Granollers, Dept Med Oncol, Granollers, Spain

[8] Hosp Clin Barcelona, Dept Med Oncol, Barcelona, Spain

[9] Xarxa Assistencial Univ Manresa, Hosp St Joan Deu Althaia, Med Oncol, Manresa, Spain

来源：

ANNALS OF ONCOLOGY | 2024年 / 35卷

关键词：

D O I：

10.1016/j.annonc.2024.08.1726

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

1645P

引用

页码：S992 / S992

页数：1

共 50 条

[41] Approval for Zytiga® in metastatic hormone-sensitive Prostate Cancer
Junker, Annette
ONCOLOGY RESEARCH AND TREATMENT, 2018, 41 (03) : 152 - 152
[42] Modern treatment of metastatic hormone-sensitive prostate cancer
Kuronya Zsofia
Biro Krisztina
Geczi Lajos
Maraz Aniko
ORVOSI HETILAP, 2018, 159 (41) : 1664 - 1671
[43] Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate Cancer
Sweeney, Christopher J.
Chen, Yu-Hui
Carducci, Michael
Liu, Glenn
Jarrard, David F.
Eisenberger, Mario
Wong, Yu-Ning
Hahn, Noah
Kohli, Manish
Cooney, Matthew M.
Dreicer, Robert
Vogelzang, Nicholas J.
Picus, Joel
Shevrin, Daniel
Hussain, Maha
Garcia, Jorge A.
DiPaola, Robert S.
NEW ENGLAND JOURNAL OF MEDICINE, 2015, 373 (08): : 737 - 746
[44] Darolutamide: A Review in Metastatic Hormone-Sensitive Prostate Cancer
Arnold Lee
Targeted Oncology, 2023, 18 : 793 - 800
[45] Optimal treatment for metastatic hormone-sensitive prostate cancer
Omlin, A.
ONCOLOGY RESEARCH AND TREATMENT, 2020, 43 (SUPPL 4) : 18 - 19
[46] Prognostic Impact of Sarcopenia in Patients with Metastatic Hormone-Sensitive Prostate Cancer
Lee, Ji Hyun
Jee, Byul A.
Kim, Jae-Hun
Bae, Hoyoung
Chung, Jae Hoon
Song, Wan
Sung, Hyun Hwan
Jeon, Hwang Gyun
Jeong, Byong Chang
Seo, Seong Il
Jeon, Seong Soo
Lee, Hyun Moo
Park, Se Hoon
Kang, Minyong
CANCERS, 2021, 13 (24)
[47] Darolutamide: A Review in Metastatic Hormone-Sensitive Prostate Cancer
Lee, Arnold
TARGETED ONCOLOGY, 2023, 18 (05) : 793 - 800
[48] Advancements in the treatment of metastatic hormone-sensitive prostate cancer
Li, Hengping
Zhang, Mao
Wang, Xiangrong
Liu, Yang
Li, Xuanpeng
FRONTIERS IN ONCOLOGY, 2022, 12
[49] SYSTEMIC TRIPLE THERAPY IN METASTATIC HORMONE SENSITIVE PROSTATE CANCER (MHSPC)
Omrcen, Tomislav
ACTA CLINICA CROATICA, 2022, 61 : 81 - 85
[50] Darolutamide and Survival in Metastatic, Hormone-Sensitive Prostate Cancer
Smith, Matthew R.
Hussain, Maha
Saad, Fred
Fizazi, Karim
Sternberg, Cora N.
Crawford, E. David
Kopyltsov, Evgeny
Park, Chandler H.
Alekseev, Boris
Montesa-Pino, Alvaro
Ye, Dingwei
Parnis, Francis
Cruz, Felipe
Tammela, Teuvo L. J.
Suzuki, Hiroyoshi
Utriainen, Tapio
Fu, Cheng
Uemura, Motohide
Mendez-Vidal, Maria J.
Maughan, Benjamin L.
Joensuu, Heikki
Thiele, Silke
Li, Rui
Kuss, Iris
Tombal, Bertrand
NEW ENGLAND JOURNAL OF MEDICINE, 2022, 386 (12): : 1132 - 1142

← 1 2 3 4 5 →